Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr Barzi on the Evolution of Treating Gastroesophageal Cancers

August 30th 2023

Afsaneh Barzi, MD, PhD, discusses challenges treating oncologists face when aiming to navigate the treatment landscape of patients with gastroesophageal cancers and highlights the evolution of treatments for patients with these diseases.

Mapping Progress in Pancreatic Cancer Surgery: Looking to the Future

August 30th 2023

In this fourth episode of OncChats: Mapping Progress Made in Pancreatic Cancer Surgery, Horacio J. Asbun, MD, and Domenech Asbun, MD, project where the pancreatic cancer treatment paradigm is headed, from a surgical perspective and beyond.

Savolitinib Wins Breakthrough Therapy Designation in China for Gastric Cancer With MET Amplification

August 30th 2023

The Center for Drug Evaluation, of the National Medical Products Administration in China, has granted a breakthrough therapy designation to savolitinib for use in patients with locally advanced or metastatic gastric cancer or gastroesophageal junction with MET amplification in whom at least 2 lines of standard therapy have failed.

Novartis Discontinues Development of NIS793 in Pancreatic Cancer

August 30th 2023

Novartis will discontinue the development of the anti-TGFß monoclonal antibody NIS793 for the treatment of patients with pancreatic cancer and other malignancies, according to a SEC filing from Xoma.

Leveraging Endoscopic Ultrasound in Pancreatic Cancer: From Diagnosis to Personalized Treatment

August 29th 2023

In this first episode of OncChats: Leveraging Endoscopic Ultrasound in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Tamas A. Gonda, MD, discuss how endoscopic ultrasound has changed the diagnosis of pancreatic cancer and how it may also be utilized to guide personalized treatment in nonmetastatic adenocarcinomas.

Pembrolizumab Plus Trastuzumab and Chemotherapy Receives European Approval in HER2+ Gastric/GEJ Cancer

August 29th 2023

The European Commission has approved pembrolizumab for use in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic, HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 with a combined positive score of at least 1.

European Medicines Agency Grants Orphan Drug Designation to Mitazalimab for Pancreatic Cancer

August 25th 2023

The European Medicines Agency has granted orphan drug designation to mitazalimab for use in patients with pancreatic cancer.

Cabozantinib Efficacy Prompts CABINET Trial Unblinding in Advanced Pancreatic and Extra-Pancreatic NETs

August 24th 2023

Interim data from the phase 3 CABINET trial demonstrated significant improvement in progression-free survival with cabozantinib vs placebo in patients with advanced pancreatic or extra-pancreatic neuroendocrine tumors following progression on prior systemic therapy.

Mapping Progress in Pancreatic Cancer Surgery: Multidisciplinary Approach to Care

August 23rd 2023

In this third episode of OncChats: Mapping Progress Made in Pancreatic Cancer Surgery, Horacio J. Asbun, MD, and Domenech Asbun, MD, underscore the need for utilizing a multidisciplinary approach to determine the optimal care plan for each patient with pancreatic cancer.

Personalized Neoantigen Vaccine Induces Continued Responses in Pretreated, Advanced HCC

August 22nd 2023

Second-line treatment with GNOS-PV02 plus plasmid-encoded interleukin-12 followed by electroporation elicited complete molecular response detected via circulating tumor DNA in 4 additional patients with advanced hepatocellular carcinoma enrolled in the phase 1b/2a GT-30 study.

Dr Fakih on the BASECAMP-1 Study in HLA-A*0201-Positive Solid Tumors

August 21st 2023

Marwan G. Fakih, MD, discusses the main objective and design of the observational BASECAMP-1 study and how it functions alongside the phase 1/2 EVEREST-1 study in patients with solid tumors.

FDA Grants Orphan Drug Designation to MAb-AR20.5 in Pancreatic Cancer

August 21st 2023

The FDA has granted an orphan drug designation to the IgG1k type murine monoclonal antibody MAb-AR20.5 for the treatment of patients with pancreatic cancer.

CGX1321 Demonstrates Safety and Promising Activity in Advanced GI Cancers

August 21st 2023

Marios Giannakis, MD, PhD, discusses how targeting the WNT signaling pathway could harness a previously underutilized pathway involved in GI tumor development, spotlights the activity and safety of CGX1321 with or without pembrolizumab in phase 1 studies, and emphasizes the need for continued investigation of CGX1321 to further validate this precision medicine approach.

Dr Byndloss on the Relationship Between the Gut Microbiome and GI Cancers

August 18th 2023

Mariana X. Byndloss, DVM, PhD, discusses how the gut microbiome influences human health, highlighting the relationship between the gut microbiome and a person’s risk for developing gastrointestinal cancers, as well as characteristics of a healthy gut microbiome.

Ociperlimab Plus Tislelizumab/Chemo Has Antitumor Activity in Stage IV Gastric/GEJ Cancers

August 18th 2023

The combination of ociperlimab, tislelizumab, and chemotherapy elicited responses in patients with stage IV gastric or gastroesophageal junction cancer, irrespective of PD-L1 expression.

Selective Use of Neoadjuvant Chemoradiation Is a Viable Approach in Locally Advanced Rectal Cancer

August 17th 2023

Deb Schrag, MD, MPH, discusses the rationale for exploring the use of selective preoperative chemoradiation in patients with locally advanced rectal cancer, the safety and efficacy findings from the PROSPECT trial, and the importance of reviewing patient-reported outcomes during clinical trials.

FDA Grants Orphan Drug Designation to NXP800 for Cholangiocarcinoma

August 17th 2023

The FDA has granted an orphan drug designation to NXP800 for the treatment of patients with cholangiocarcinoma.

Mapping Progress in Pancreatic Cancer Surgery: Continuing to Move the Needle

August 16th 2023

In this second episode of OncChats: Mapping Progress Made in Pancreatic Cancer Surgery, Horacio J. Asbun, MD, and Domenech Asbun, MD, share examples of efforts that have moved the needle forward in pancreatic cancer surgery, and note potential areas of opportunity.

Updates on Imaging-Based Pancreatic Cancer Surveillance for Individuals With Increased Genetic and Familial Risk

August 15th 2023

Recent years have brought tremendous progress in demonstrating that there is hope for improving mortality from pancreatic ductal adenocarcinoma through early detection.

GVAX Cancer Vaccine Plus Nivolumab and Urelumab Elicits Early Efficacy in Pancreatic Adenocarcinoma

August 14th 2023

Treatment with the GVAX pancreatic cancer vaccine plus nivolumab and urelumab increased the presence of intratumoral activated cytotoxic T cells and showed early signs of efficacy in patients with resectable pancreatic adenocarcinoma.